Jim Cramer's Mad Dash: The Fed Is Overlooking Biotech Growth

NEW YORK (TheStreet) -- Shares of Intercept Pharmaceuticals (ICPT) are up over 30%, but are off yesterday’s after-hours highs when the stock soared 66% on a positive earnings report. 

On CNBC’s "Cramer’s Mad Dash" segment, TheStreet’s Jim Cramer, co-manager of the Action Alerts PLUS portfolio, reminded investors that Federal Reserve chair Janet Yellen recent called small-cap and mid-cap biotech stocks overvalued. 

Read More: The Keystone XL Pipeline Springs Another Leak

However, Intercept appears to have a cure for nonalcoholic steatohepatitis, a form of liver disease. 

The preliminary results are better than many had expected, Cramer said. 

“When you have a great orphan drug that does do something special, you can have this kind of move,” he added, referring to the jump in the stock price. 

Large-cap pharmaceutical companies aren't the ones generating growth; biotech companies are. The Federal Reserve was "misplaced" calling the industry overvalued, Cramer concluded.

-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

Read More: Kinder Morgan Consolidation: What It Means for MLPs

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Intercept Sinks on Safety Issue, One Analyst Says Buy Anyway - Biotech Movers

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

Clovis Sell-Off May Be Overdone